A Feasibility Study for Determining Ablative Margin with 3D-CEUS-CT/MR Image Fusion after Radiofrequency Ablation of Hepatocellular Carcinoma

Abstract

Purpose: To explore the feasibility and value of 3D-CEUS-CT/MR image fusion in evaluating ablative margin (AM) after radiofrequency ablation of hepatocellular carcinoma.

Methods and materials: There were 49 HCC in 41 patients enrolled in our prospective study. The AM were evaluated with 3D-CEUS-CT/MR image fusion, the results were divided into two groups: in group A, the tumor was completely ablated with a 5 mm AM; in group B, the tumor was completely ablated, but a 5 mm AM was not obtained. The time used in US-CT/MR image fusion and 3 D image post-processing, the technical success rate of 3D-CEUS-CT/MR image fusion and the relation between LTP and AM were observed.

Results: The time taken for US-CT/MR image fusion and 3 D image post-processing was 9.2 ± 2.1 min (6 – 12 min), 14.6 ± 2.6 min (9 – 20 min), respectively. The technical success rate of 3D-CEUS-CT/MR image fusion was 81.6 % (40/49). 27 HCC had sufficient AM (group A) and 13 HCC had insufficient AM (group B). The LTP rates in groups A and B were 0/27 and 4/13, respectively. There was a significant difference between groups A and B (P = 0.002). There was a significant negative correlation between LTP and AM (r = –1.000, P< 0.001), and the locations of LTP and insufficient AM were concordant.

Conclusions: The results suggest that 3D-CEUS-CT/MR image fusion is feasible and useful in evaluating the AM after HCC ablation.

Zusammenfassung

Ziel: Untersuchung der Durchführbarkeit und des Wertes der 3DCEUS-CT/MR-Bildfusion zur Beurteilung des Ablationsrandes (ablative margin = AM) nach Radiofrequenzablation des hepatozellulären Karzinoms (HCC).

Material und Methoden: In unsere prospektive Studie wurden 49 HCCs von 41 Patienten aufgenommen. Der AM wurde mittels 3D-CEUS-CT/MR-Bildfusion beurteilt und die Ergebnisse in zwei Gruppen aufgeteilt: Gruppe A mit kompletter Ablation des Tumors und einem 5 mm großem AM, Gruppe B mit kompletter Tumorablation ohne Erhalt eines 5 mm AM. Der Zeitaufwand der 3D-CEUS-CT/MR-Bildfusion und der 3D-Bild-Nachbearbeitung, die technische Erfolgsrate der 3D-CEUS-CT/MR Bildfusion sowie das Verhältnis zwischen LTP und AM wurden verfolgt.

Ergebnisse: Der Zeitaufwand für die US-CT/MR Bildfusion betrug 9,2 ± 2,1 min (6 – 12 min) und für die 3D-Bild-Nachbearbeitung 14,6 ± 2,6 min (9 – 20 min). Die technische Erfolgsrate der 3D-CEUS-CT/MR-Bildfusion betrug 81,6 % (40/49). Einen ausreichenden AM (Gruppe A) hatten 27 HCC und einen nicht ausreichenden AM (Gruppe B)13 HCCs. Die LTP-Raten (local tumor progression) in Gruppe A betrugen 0/27 und in Gruppe B 4/13 mit einem signifikanten Unterschied zwischen beiden Gruppen (p = 0,002). Zwischen LTP und AM wurde eine signifikante negative Korrelation beobachtet (r = –1,000, p < 0,001) und die Bereiche von LTP und nicht ausreichendem AM stimmten überein.

Schlussfolgerung: Die Ergebnisse weisen auf die Durchführbarkeit der 3D-CEUS-CT/MR-Bildfusion hin und auf deren Wert für die Beurteilung des AM nach HCC-Ablation.

Key words

3-D ultrasound - radiofrequency (RF) ablation - treatment effects - tumor - MR-imaging

• References

• 1 Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236
• 2 Zhou YM, Zhao YF, Li B et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterology 2010; 10: 78-84
• 3 Liu ZH, Zhou YK, Zhang P et al. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech 2010; 20: 130-140
• 4 Kei SK, Rhim H, Choi D et al. Local tumor progression after radiofrequency ablation of liver tumors: analysis of morphologic pattern and site of recurrence. Am J Roentgenol 2008; 190: 1544-1551
• 5 Kim Y, Rhim H, Cho OK et al. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006; 59: 432-441
• 6 Zytoon AA, Ishii H, Murakami K et al. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma: a registry report of the impact of risk factors on outcome. Jpn J Clin Oncol 2007; 37: 658-672
• 7 Nakazawa T, Kokubu S, Shibuya A et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. Am J Roentgenol 2007; 188: 480-488
• 8 Mori K, Fukuda K, Asaoka H et al. Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran – feasibility study. Radiology 2009; 251: 557-565
• 9 Kim YS, Lee WJ, Rhim H et al. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. Am J Roentgenol Am J Roentgenol 2010; 195: 758-765
• 10 Ricci P, Cantisani V, Drudi F et al. Is contrast-enhanced US alternative to spiral CT in the assessment of treatment outcome of radiofrequency ablation in hepatocellular carcinoma?. Ultraschall in Med 2009; 30: 252-258
• 11 Perez-Rodriguez J, Lai S, Ehst BD et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment – report of 33 cases. Radiology 2009; 250: 371-377
• 12 Xu HX, Lu MD, Xie XH et al. Treatment response evaluation with three dimensional contrast-enhanced ultrasound for liver cancer after local therapies. Eur J Radiol 2010; 76: 81-88
• 13 Wood BJ, Locklin JK, Viswanathan A et al. Technologies for Guidance of Radiofrequency Ablation in the Multimodality Interventional Suite of the Future. J Vasc Interv Radiol 2007; 18: 9-24
• 14 Crocetti L, Lencioni R, Debeni S et al. Target liver lesions for radiofrequency ablation: an experimental feasibility study using CT-US fusion system. Invest Radiol 2008; 43: 33-39
• 15 Jung EM, Schreyer AG, Schacherer D et al. New real-time image fusion technique for characterization of tumor vascularisation and tumor perfusion of liver tumors with contrast-enhanced ultrasound, spiral CT or MRI: First results. Clin Hemorheol Microcirc 2009; 43: 57-69
• 16 Bruix J, Sherman M American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
• 17 Goldberg SN, Grassi CJ, Cardella JF et al. Society of Interventional Radiology Technology Assessment Committee Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 2005; 235: 728-739
• 18 Kurokohchi K, Watanabe S, Yoneyama H et al. A combination therapy of ethanol injection and radiofrequency ablation under general anesthesia for the treatment of hepatocellular carcinoma. World J Gastroenterol 2008; 14: 2037-2043